Mei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mei Huang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Guozhen Cui
Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China
1 shared publication - Jiachao Li
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519000, China
1 shared publication - Jiansong Fang
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication - Mei Zhou
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519000, China
1 shared publication - Mengchen Liu
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519000, China
1 shared publication - Mingxuan Ma
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519000, China
1 shared publication
Latest Publications
- Open Access
- 6 July 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 899
Network Medicine: A Potential Approach for Virtual Drug Screening
Traditional drug screening methods typically focus on a single protein target and exhibit limited efficiency due to the multifactorial nature of most diseases, which result from disturbances within complex networks of protein–protein interactions rather than single gene abnormalities. Addressing this limitation requires a comprehensive drug screening strategy. Network medicine is rooted in systems biology and provides a comprehensive framework for understanding disease mechanisms, prevention, and therapeutic innovations. This approach not only explores the associations between various diseases but also quantifies the relationships between disease genes and drug targets within interactome networks, thus facilitating the prediction of drug–disease relationships and enabling the screening of therapeutic drugs for specific complex diseases. An increasing body of research supports the efficiency and utility of network-based strategies in drug screening. This review highlights the transformative potential of network medicine in virtual therapeutic screening for complex diseases, offering novel insights and a robust foundation for future drug discovery endeavors.
- 6 July 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 899
Open AccessNetwork Medicine: A Potential Approach for Virtual Drug Screening
Traditional drug screening methods typically focus on a single protein target and exhibit limited efficiency due to the multifactorial nature of most diseases, which result from disturbances within complex networks of protein–protein interactions rather than single gene abnormalities. Addressing this limitation requires a comprehensive drug screening strategy. Network medicine is rooted in systems biology and provides a comprehensive framework for understanding disease mechanisms, prevention, and therapeutic innovations. This approach not only explores the associations between various diseases but also quantifies the relationships between disease genes and drug targets within interactome networks, thus facilitating the prediction of drug–disease relationships and enabling the screening of therapeutic drugs for specific complex diseases. An increasing body of research supports the efficiency and utility of network-based strategies in drug screening. This review highlights the transformative potential of network medicine in virtual therapeutic screening for complex diseases, offering novel insights and a robust foundation for future drug discovery endeavors.